Dupilumab
- Generic Name
- Dupilumab
- Brand Names
- Dupixent
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1190264-60-8
- Unique Ingredient Identifier
- 420K487FSG
- Background
Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reacti...
- Indication
In the US, dupilumab is indicated for the treatment of patients aged six months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. In Europe and Canada, the drug for this indication is approved for patients aged six years and older. In E...
- Associated Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Eosinophilic Esophagitis, Moderate to Severe Asthma, Moderate to Severe Atopic Dermatitis, Oral Steroid-Dependent Asthma (Disorder), Prurigo Nodularis, Severe Asthma, Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate Prurigo Nodularis, Severe Prurigo Nodularis
- Associated Therapies
- Add-on therapy, Maintenance therapy
Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 94
- Registration Number
- NCT03861455
- Locations
- 🇫🇷
CHU Lyon-Sud Département d'allergologie et d'immunologie clinique, Pierre-Bénite, France
🇫🇷Saint André Hospital, Bordeaux, France
🇫🇷Hôpital Saint Eloi, Montpellier, France
Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy
- First Posted Date
- 2019-01-04
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT03793608
- Locations
- 🇨🇦
Regeneron Investigational Site, Montreal, Quebec, Canada
Dupilumab in Chronic Spontaneous Urticaria
- Conditions
- Interventions
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 72
- Registration Number
- NCT03749135
- Locations
- 🇩🇪
Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany
🇩🇪Hautklinik der Universitätsmedizin Mainz Clinical Research Center, Mainz, Rheinland-Pfalz, Germany, Germany
🇩🇪Universitätsklinikum Giessen und Marburg, Marburg, Hessen, Germany
Cholinergic Urticaria - Efficacy of Dupilumab
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 48
- Registration Number
- NCT03749148
- Locations
- 🇩🇪
Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany
🇩🇪Charité-Universitätsmedizin Berlin, Berlin, Germany
🇩🇪Hautklinik Universitätsklinikum Münster, Münster, Nordrhein-Westfalen, Germany
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 206
- Registration Number
- NCT03736967
- Locations
- 🇪🇸
Regeneron Research Site, Santiago de Compostela, Spain
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 838
- Registration Number
- NCT03720470
- Locations
- 🇺🇸
Moonshine Research Center, Inc., Doral, Florida, United States
🇺🇸PMG Research of Raleigh, LLC d/b/a PMG Research of Cary, Cary, North Carolina, United States
🇨🇦Toronto Research Centre, Toronto, Ontario, Canada
Investigating Dupilumab's Effect in Asthma by Genotype
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT03694158
- Locations
- 🇺🇸
MetroHealth System, Cleveland, Ohio, United States
🇺🇸Atlantic Health System, Cedar Knolls, New Jersey, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
- Conditions
- Interventions
- First Posted Date
- 2018-09-25
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 148
- Registration Number
- NCT03682770
- Locations
- 🇺🇸
Regeneron Investigational Site, Seattle, Washington, United States
Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)
- Conditions
- Interventions
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 108
- Registration Number
- NCT03679676
- Locations
- 🇺🇸
University of California San Diego (UCSD), San Diego, California, United States
🇺🇸University of California Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸Sean N. Parker Center for Allergy & Asthma Research at Stanford University, Palo Alto, California, United States
Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT03675022
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.